TA Traina

Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC)

Heather L. McArthur, Cherry L. Estilo, Joseph M. Huryn et al. · Journal of Clinical Oncology · 2008 · 28 citations

Medicine, Oncology, Pharmacology +9

Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC)

TA Traina, Hope S. Rugo, James F. Caravelli et al. · Journal of Clinical Oncology · 2006 · 26 citations

Medicine, Oncology, Pharmacology +17

Cardiac safety of adjuvant bevacizumab (B) plus dose-dense doxorubicin/cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel (nab-P) in patients with early stage breast cancer.

HL McArthur, Hope Rugo, Benjamin Nulsen et al. · Cancer Research · 2009 · 14 citations

Medicine, Oncology, Pharmacology +17

Change in circulating endothelial cells (CEC) predicts progression free survival (PFS) in patients (pts) with hormone receptor positive metastatic breast cancer (MBC) receiving letrozole (L) and bevacizumab (B)

Hope S. Rugo, Maura N. Dickler, TA Traina et al. · Journal of Clinical Oncology · 2006 · 14 citations

Medicine, Oncology, Pharmacology +17

Phase II study of weekly nanoparticle albumin bound (nab)paclitaxel with carboplatin and trastuzumab as 1st-line therapy for HER2-positive metastatic breast cancer (MBC)

A. D. Seidman, Alison Conlin, A M Bach et al. · Journal of Clinical Oncology · 2008 · 10 citations · Full text

Medicine, Oncology, Pharmacology +17